In many R&D programs, the bottleneck is not “whether a molecule does something,” but whether it can work stably and controllably in real systems—i.e., whether it falls within a developable property window.
A recurring tension in medicinal design is this: you want stronger binding, better solubility/exposure, more controllable metabolism and selectivity—without tearing down and rebuilding the entire scaffold. Over the past decade-plus, “small, polar, sp³-rich” four-membered rings—oxetanes ...
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.